These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
303 related articles for article (PubMed ID: 23034390)
1. Increased TMEM16A-encoded calcium-activated chloride channel activity is associated with pulmonary hypertension. Forrest AS; Joyce TC; Huebner ML; Ayon RJ; Wiwchar M; Joyce J; Freitas N; Davis AJ; Ye L; Duan DD; Singer CA; Valencik ML; Greenwood IA; Leblanc N Am J Physiol Cell Physiol; 2012 Dec; 303(12):C1229-43. PubMed ID: 23034390 [TBL] [Abstract][Full Text] [Related]
2. Potent vasorelaxant activity of the TMEM16A inhibitor T16A(inh) -A01. Davis AJ; Shi J; Pritchard HA; Chadha PS; Leblanc N; Vasilikostas G; Yao Z; Verkman AS; Albert AP; Greenwood IA Br J Pharmacol; 2013 Feb; 168(3):773-84. PubMed ID: 22946562 [TBL] [Abstract][Full Text] [Related]
3. Chronic hypoxia-induced upregulation of Ca2+-activated Cl- channel in pulmonary arterial myocytes: a mechanism contributing to enhanced vasoreactivity. Sun H; Xia Y; Paudel O; Yang XR; Sham JS J Physiol; 2012 Aug; 590(15):3507-21. PubMed ID: 22674716 [TBL] [Abstract][Full Text] [Related]
4. Intricate interaction between store-operated calcium entry and calcium-activated chloride channels in pulmonary artery smooth muscle cells. Forrest AS; Angermann JE; Raghunathan R; Lachendro C; Greenwood IA; Leblanc N Adv Exp Med Biol; 2010; 661():31-55. PubMed ID: 20204722 [TBL] [Abstract][Full Text] [Related]
5. Coronary hypercontractility to acidosis owes to the greater activity of TMEM16A/ANO1 in the arterial smooth muscle cells. Guo P; Liu Y; Xu X; Ma G; Hou X; Fan Y; Zhang M Biomed Pharmacother; 2021 Jul; 139():111615. PubMed ID: 34243598 [TBL] [Abstract][Full Text] [Related]
6. Resveratrol reverses monocrotaline-induced pulmonary vascular and cardiac dysfunction: a potential role for atrogin-1 in smooth muscle. Paffett ML; Lucas SN; Campen MJ Vascul Pharmacol; 2012; 56(1-2):64-73. PubMed ID: 22146233 [TBL] [Abstract][Full Text] [Related]
10. TMEM16A Ca Suzuki T; Yasumoto M; Suzuki Y; Asai K; Imaizumi Y; Yamamura H Mol Pharmacol; 2020 Jul; 98(1):61-71. PubMed ID: 32358165 [TBL] [Abstract][Full Text] [Related]
11. Icotinib Attenuates Monocrotaline-Induced Pulmonary Hypertension by Preventing Pulmonary Arterial Smooth Muscle Cell Dysfunction. Peng LY; Yu M; Yang MX; Liu P; Zhou H; Huang W; Kong H; Xie WP Am J Hypertens; 2020 Aug; 33(8):775-783. PubMed ID: 32301965 [TBL] [Abstract][Full Text] [Related]
12. [TRPC6 mediates the enhancements of pulmonary arterial tone and intracellular Ca2+ concentration of pulmonary arterial smooth muscle cells in pulmonary hypertension rats]. Zhang MF; Liu XR; Yang N; Lin MJ Sheng Li Xue Bao; 2010 Feb; 62(1):55-62. PubMed ID: 20179889 [TBL] [Abstract][Full Text] [Related]
14. Imatinib attenuates monocrotaline pulmonary hypertension and has potent vasodilator activity in pulmonary and systemic vascular beds in the rat. Pankey EA; Thammasiboon S; Lasker GF; Baber S; Lasky JA; Kadowitz PJ Am J Physiol Heart Circ Physiol; 2013 Nov; 305(9):H1288-96. PubMed ID: 23997103 [TBL] [Abstract][Full Text] [Related]
15. Tetrandrine prevents monocrotaline-induced pulmonary arterial hypertension in rats through regulation of the protein expression of inducible nitric oxide synthase and cyclic guanosine monophosphate-dependent protein kinase type 1. Wang X; Yang Y; Yang D; Tong G; Lv S; Lin X; Chen C; Dong W J Vasc Surg; 2016 Nov; 64(5):1468-1477. PubMed ID: 26527422 [TBL] [Abstract][Full Text] [Related]
16. Niflumic Acid Attenuated Pulmonary Artery Tone and Vascular Structural Remodeling of Pulmonary Arterial Hypertension Induced by High Pulmonary Blood Flow In Vivo. Wang K; Ma J; Pang Y; Lao J; Pan X; Tang Q; Zhang F; Su D; Qin S; Shrestha AP J Cardiovasc Pharmacol; 2015 Oct; 66(4):383-91. PubMed ID: 26132368 [TBL] [Abstract][Full Text] [Related]
17. PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats. Porvasnik SL; Germain S; Embury J; Gannon KS; Jacques V; Murray J; Byrne BJ; Shacham S; Al-Mousily F J Pharmacol Exp Ther; 2010 Aug; 334(2):364-72. PubMed ID: 20430844 [TBL] [Abstract][Full Text] [Related]
18. Neutralization of CXCL12 attenuates established pulmonary hypertension in rats. Bordenave J; Thuillet R; Tu L; Phan C; Cumont A; Marsol C; Huertas A; Savale L; Hibert M; Galzi JL; Bonnet D; Humbert M; Frossard N; Guignabert C Cardiovasc Res; 2020 Mar; 116(3):686-697. PubMed ID: 31173066 [TBL] [Abstract][Full Text] [Related]
19. Targeting TMEM16A to reverse vasoconstriction and remodelling in idiopathic pulmonary arterial hypertension. Papp R; Nagaraj C; Zabini D; Nagy BM; Lengyel M; Skofic Maurer D; Sharma N; Egemnazarov B; Kovacs G; Kwapiszewska G; Marsh LM; Hrzenjak A; Höfler G; Didiasova M; Wygrecka M; Sievers LK; Szucs P; Enyedi P; Ghanim B; Klepetko W; Olschewski H; Olschewski A Eur Respir J; 2019 Jun; 53(6):. PubMed ID: 31023847 [TBL] [Abstract][Full Text] [Related]